Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer’s mouse model

Latrepirdine (Dimebon™) is a pro-neurogenic, antihistaminic compound that has yielded mixed results in clinical trials of mild to moderate Alzheimer’s disease, with a dramatically positive outcome in a Russian clinical trial that was unconfirmed in a replication trial in the United States. We sought...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Steele, John W., Lachenmayer, M. Lenard, Ju, Shulin, Stock, Aryeh, Liken, Jessica, Kim, Soong Ho, Delgado, Luz M., Alfaro, Iván E, Bernales, Sebastian, Verdile, Giuseppe, Bharadwaj, Prashant, Gupta, Veer, Barr, Renae, Friss, Amy, Dolios, Georgia, Wang, Rong, Ringe, Dagmar, Fraser, Paul, Westaway, David, St George-Hyslop, Peter H., Szabo, Paul, Relkin, Norman R., Buxbaum, Joseph D., Glabe, Charles G., Protter, Andrew A., Martins, Ralph N., Ehrlich, Michelle E., Petsko, Gregory A., Yue, Zhenyu, Gandy, Sam
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2012
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3625697/
https://ncbi.nlm.nih.gov/pubmed/22850627
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mp.2012.106
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia